Jove
Visualize
Contact Us

Related Experiment Videos

Dose optimization of anthracyclines

D de Valeriola1

  • 1Institut Jules Bordet, Unité d'Oncopharmacologie, Brussels, Belgium.

Anticancer Research
|November 1, 1994
PubMed
Summary
This summary is machine-generated.

Optimal anthracycline dosing remains undefined despite extensive research. Further studies on pharmacokinetic-pharmacodynamic relationships are crucial for maximizing anticancer efficacy and minimizing toxicity in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Need for global action for cancer control.

Annals of oncology : official journal of the European Society for Medical Oncology·2008
Same author

Adjuvant chemotherapy in 2005: standards and beyond.

Breast (Edinburgh, Scotland)·2005
Same author

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.

British journal of cancer·2005
Same author

Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers.

Anti-cancer drugs·2004
Same author

Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules.

Annals of oncology : official journal of the European Society for Medical Oncology·2002
Same author

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2002
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Oncology
  • Clinical Pharmacy

Background:

  • Anthracyclines are vital anticancer drugs with well-studied pharmacokinetics.
  • Optimal dosage regimens and clear pharmacokinetic-pharmacodynamic (PK-PD) relationships are still lacking.

Purpose of the Study:

  • To review existing PK-PD relationships for anthracyclines.
  • To highlight the need for further research to optimize anthracycline dosing.

Main Methods:

  • Literature review of pharmacokinetic-pharmacodynamic studies on anthracyclines.
  • Analysis of data regarding anthracycline efficacy and toxicity.

Main Results:

  • Prolonged infusion/fractionated schedules may reduce doxorubicin cardiotoxicity, but efficacy compared to IV bolus is unproven.

Related Experiment Videos

  • Insufficient data exist to identify optimal PK parameters for predicting myelosuppression, other toxicities, or tumor response.
  • Current anthracycline dose adjustments for liver dysfunction lack a strong scientific basis.

    • Conclusions:

    • Significant research is needed to elucidate anthracycline pharmacodynamics.
    • Limited sampling strategies can aid in establishing PK-PD relationships.
    • Optimizing anthracycline dosage requires a better understanding of PK-PD to balance efficacy and toxicity.